These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 8736622)

  • 21. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
    Chan S
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).
    Pazdur R; Kudelka AP; Kavanagh JJ; Cohen PR; Raber MN
    Cancer Treat Rev; 1993 Oct; 19(4):351-86. PubMed ID: 8106152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers.
    Wiseman LR; Spencer CM
    Drugs Aging; 1998 Apr; 12(4):305-34. PubMed ID: 9571394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The current status of docetaxel for metastatic breast cancer.
    Esteva FJ
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):17-26. PubMed ID: 12108894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects.
    Pronk LC; Stoter G; Verweij J
    Cancer Treat Rev; 1995 Sep; 21(5):463-78. PubMed ID: 8556719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An overview of phase II studies of docetaxel in patients with metastatic breast cancer.
    Eisenhauer EA; Trudeau M
    Eur J Cancer; 1995; 31A Suppl 4():S11-3. PubMed ID: 7577098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.
    Lamb HM; Wiseman LR
    Pharmacoeconomics; 1998 Oct; 14(4):447-59. PubMed ID: 10344911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Docetaxel: a review of its use in metastatic breast cancer.
    Lyseng-Williamson KA; Fenton C
    Drugs; 2005; 65(17):2513-31. PubMed ID: 16296875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docetaxel.
    Cortes JE; Pazdur R
    J Clin Oncol; 1995 Oct; 13(10):2643-55. PubMed ID: 7595719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-agent docetaxel (Taxotere) in randomized phase III trials.
    Burris HA
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Chevallier B; Fumoleau P; Kerbrat P; Dieras V; Roche H; Krakowski I; Azli N; Bayssas M; Lentz MA; Van Glabbeke M
    J Clin Oncol; 1995 Feb; 13(2):314-22. PubMed ID: 7844592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent progress in the clinical development of docetaxel (Taxotere).
    Hortobagyi GN
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):32-6. PubMed ID: 10426457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolution in the treatment of advanced breast cancer.
    Crown J
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):12-7. PubMed ID: 9865706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The scientific rationale for developing taxoids.
    Aapro M
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():33-6. PubMed ID: 8862709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer.
    Ravdin PM; Valero V
    Semin Oncol; 1995 Apr; 22(2 Suppl 4):17-21. PubMed ID: 7740326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers.
    Montana M; Ducros C; Verhaeghe P; Terme T; Vanelle P; Rathelot P
    J Chemother; 2011 Apr; 23(2):59-66. PubMed ID: 21571619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer.
    Ravdin PM
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-18-S10-21. PubMed ID: 9275002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
    Hudis CA; Seidman AD; Crown JP; Balmaceda C; Freilich R; Gilewski TA; Hakes TB; Currie V; Lebwohl DE; Baselga J; Raptis G; Gollub M; Robles M; Bruno R; Norton L
    J Clin Oncol; 1996 Jan; 14(1):58-65. PubMed ID: 8558221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial.
    Hainsworth JD; Burris HA; Yardley DA; Bradof JE; Grimaldi M; Kalman LA; Sullivan T; Baker M; Erland JB; Greco FA
    J Clin Oncol; 2001 Aug; 19(15):3500-5. PubMed ID: 11481356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.
    Trudeau ME; Eisenhauer EA; Higgins BP; Letendre F; Lofters WS; Norris BD; Vandenberg TA; Delorme F; Muldal AM
    J Clin Oncol; 1996 Feb; 14(2):422-8. PubMed ID: 8636752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.